Redmile Group’s Privia Health PRVA Stock Holding History

Redmile Group’s Portfolio PRVA Stock Details PRVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-206,113	Closed	-$6M	–	73
2022 Q2	$6M	Buy	+206,113	New	+$5.24M	0.23%	58

Other funds holding PRVA

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Redmile Group's PRVA Position: Q3 2022 in Review

Redmile Group sold out of Privia Health (PRVA) in Q3 2022, closing a stake of 206,113 shares — an estimated $6M sold.

Redmile Group first reported a position in PRVA in Q2 2022 and held it in 1 quarter. The position peaked at $6M in Q2 2022. 203 funds tracked by Wall St. Rank hold PRVA as of Q3 2022.

Redmile Group reported no remaining Privia Health position as of Q3 2022 after selling out during the quarter.
Redmile Group sold 206,113 Privia Health shares in Q3 2022, an estimated $6M.
Redmile Group first reported a position in Privia Health in Q2 2022 and held it in 1 quarter.
Redmile Group's Privia Health position peaked at $6M in Q2 2022.
203 funds tracked by Wall St. Rank held Privia Health as of Q3 2022.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.